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Abstract
Background: Human herpesvirus 6 (HHV-6), mostly variant B reactivation in renal transplant patients has been
published by other authors, but the pathogenetic role of HHV-6 variant A has not been clarified. Our aims were to
examine the prevalence of HHV-6, to determine the variants, and to investigate the interaction between HHV-6
viraemia, human cytomegalovirus (HCMV) infection and clinical symptoms.
Methods: Variant-specific HHV-6 nested PCR and quantitative real-time PCR were used to examine blood samples
from renal transplant patients and healthy blood donors for the presence and load of HHV-6 DNA and to
determine the variants. Active HHV-6 infection was proved by RT-PCR, and active HCMV infection was diagnosed
by pp65 antigenaemia test.
Results: HHV-6 viraemia was significantly more frequent in renal transplant patients compared to healthy blood
donors (9/200 vs. 0/200; p = 0.004), while prevalence of HHV-6 latency was not significantly different (13/200 vs.
19/200; p > 0.05). Dominance of variant A was revealed in viraemias (8/9), and the frequency of HHV-6A was
significantly higher in active infections compared with latency in renal transplant patients (8/9 vs. 2/13; p = 0.0015).
Latency was established predominantly by HHV-6B both in renal transplant patients and in healthy blood donors
(11/13 and 18/19). There was no statistical significant difference in occurrence of HCMV and HHV-6 viraemia in
renal transplant patients (7/200 vs. 9/200). Statistical analysis did not reveal interaction between HHV-6 viraemia
and clinical symptoms in our study.
Conclusions: Contrary to previous publications HHV-6A viraemia was found to be predominant in renal transplant
patients. Frequency of variant A was significantly higher in cases of active infection then in latency.
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Background
Immunosuppression associated with renal transplanta-
tion presents a risk for opportunistic infections, reactiva-
tions and reinfections. Human herpesvirus 6 (HHV-6) is
an important pathogen in transplant recipients. HHV-6
is ubiquitous in the population, primary infection occurs
in early childhood after which latency is established and
the seropositivity exceeds 90% [1]. There are two distinct
variants of HHV-6 [2]: variants A and B (HHV-6A,
HHV-6B). Primary infection almost always occurs with
HHV-6B [3], but it is not clarified when HHV-6A infec-
tion takes place. HHV-6 infection in transplant patients
may be the result of donor transmission, reactivation of
latent infection in the recipients or reinfection [4]. HHV-
6 reactivation occurs early, 38-60% of the patients are
affected 2-4 weeks after transplantation [5-7], but late
infections up to 2 years has been also described [8,9].
Infection is often asymptomatic [10], but reactivations
can result in fever, rash, thrombocytopenia, leukopenia,
pneumonia, hepatitis, pancreatitis, colitis, encephalitis,
meningoencephalitis, even prolonged bone marrow
suppression [4]. HHV-6 can also modulate the immune
system which can result in spread and persistence of
HHV-6 and can enhance the effects of other infection
[11]. There is increasing evidence for simultaneous reac-
tivation of HHV-6 and HCMV [12-15], an action which
predicts higher risk for severe disease [15]. It is also sug-
gested that HHV-6 reactivation occurs earlier than
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HCMV [12,14] which may indicate that HHV-6 can play
a role in the reactivation of HCMV by induction of
immunosuppression or by interaction with HCMV. In
peripheral blood samples of renal transplant patients
HHV-6 variant B is more frequently isolated [16,17], but
variant A may be more virulent [18]. The aims of this
study were to investigate the prevalence of HHV-6 infec-
tion in renal transplant patients at different times after
transplantation, to determine the subtype of HHV-6, and
to examine the possible association of HHV-6 infection
with HCMV reactivation and clinical symptoms.
Results
HHV-6 viraemia
Twelve plasma and white blood cells (WBC) samples (6%)
of 12 renal transplant patients were HHV-6 DNA positive.
Dominance of HHV-6 variant A was revealed (10/12). The
level of HHV-6A DNA in plasma samples ranged from
7.5 × 102 to 6 × 105 (median 5.9 × 103) genome equiva-
lent/mL (GEq/mL), while the copy number of HHV-6B
genome was below the limit of detection (less then
250 GEq/mL). In WBC samples HHV-6 DNA load ranged
from 5.1 × 102 to 2.1 × 106 (median 1.8 × 103) GEq/1.5
x106 cells. Three samples were negative for HHV-6
mRNA, while RT-PCR proved active HHV-6 infection in
nine samples (8 HHV-6A and 1 HHV-6B; Table 1).
Statistical analysis did not reveal significant age differ-
ences between HHV-6 positive (range 17.9-61.7 years;
median 37.8 years) and negative (11.2-68.8 years; median
45.4 years) patients. There was also not significant dif-
ference between the time of sample taking after the
transplantation of HHV-6 positive (range 21 days-13.1
years; median 6.2 years) and negative (range 3 days-19.6
years, median 3.3 years) patients.
Among healthy blood donors HHV-6 DNA, variant A
was detected in both the plasma and WBC of one sam-
ple; 5.8 × 103 GEq/1.5 × 106 WBC was measured, but
the viral load in plasma was below the limit of detection.
RT-PCR did not confirm active infection (Table 1).
HHV-6 latency
HHV-6 latency was revealed in 13 renal transplant
patients (6.5%; 11 HHV-6B and 2 HHV-6A; Table 1).
HHV-6 DNA was detected only in WBC. HHV-6
mRNA was not found in these samples.
HHV-6 DNA was found in WBC without active HHV-
6 replication in 19 healthy blood donors (9.5%; 18 HHV-
6B and 1 HHV-6A; Table 1).
HCMV reactivation
Seven patients (3.5%) had HCMV reactivation shown by
detection of pp65 antigen in WBC.
Statistical analysis did not show significant age differ-
ences between HCMV positive (range 44.1-61.6 years;
median 55.4 years) and negative (11.2-65.7 years; median
44.8 years) patients. There was also not significant dif-
ference between the time of sample taking after the
transplantation of HCMV positive (range 50 days-15.7
years; median 0.3 years) and negative (range 21 days-
13.1 years, median 6 years) patients.
Simultaneous presence of HCMV and HHV-6 virae-
mia was not detected.
Clinical data
Thirty one patients did not have clinical symptoms;
fever, respiratory and gastrointestinal symptoms were
observed in 169 patients (Table 2). All the patients had
good graft functions at the time of the examination.
Statistical analyses of HHV-6 viraemia and clinical
symptoms did not reveal association between the pre-
sence of virus and the observed clinical symptoms.
Discussion
In this study significantly higher prevalence of HHV-6
viraemia was found among renal transplant patients then
among healthy blood donors (9/200 vs. 0/200; p = 0.004).
The frequency of HHV-6 infection was not significantly
different from the frequency of HCMV reactivation
(9/200 vs. 7/200; p > 0.05). Previous reports have noted
that HHV-6 viraemia was found early, but also late after
transplantation [4,13,14]. Significant difference was not
found between HHV-6 positive and negative patients
regarding the days after transplantation at the time of
sample collection (p > 0.05). HHV-6 is able to establish
latency and integrate into human chromosomes, hence
viral DNA can originate from lysis of cells. The incidence
Table 1 Prevalence of HHV-6 and HHV-6 variants A and B in renal transplant patients and healthy controls
Viraemia Latency
Transplant Healthy Transplant Healthy
HHV-6 (all) 9/200 0/200 13/200 19/200
p = 0.004 p > 0.05
HHV-6B 1/9 0/0 11/13 18/19
HHV-6A 8/9 0/0 2/13 1/19
p = 0.0015
Csoma et al. Virology Journal 2011, 8:403
http://www.virologyj.com/content/8/1/403
Page 2 of 5
of chromosomally integrated HHV-6 (CIHHV-6) is about
0.2-3% [19-21]. Individuals with CIHHV-6 have signifi-
cant viral load, over million of GEq/mL blood; infection
or reactivation usually results in only tens of thousands
GEq/mL. It is also suggested that finding of variant A
indicates CIHHV-6 rather then active infection [20,22].
CIHHV-6 can also be reactivated and cells harbouring
CIHHV-6 will produce infectious viral particles [23,24].
In this study, the viral load detected in the blood samples
of the renal transplant patients were in accordance with
average DNA load of active HHV-6 infections.
Contrary to some previous publications [17,25-27],
HHV-6A viraemia was found to be more frequent (eight
out of nine HHV-6 positive samples) in renal transplant
individuals then HHV-6 variant B. Nowadays, effective
immunosuppressive protocols with new drugs result in
improved survival of grafts in organ transplant patients.
However, owing to the strong immunosuppression infec-
tion and consequently hospitalization is increasing among
renal transplant patients [4]. Nearly all of the symptomatic
primary HHV-6 infections in children are caused by var-
iant B, and HHV-6B is detected predominantly in healthy
individuals. HHV-6A has been identified rarely, but often
in severe inflammatory and neurological diseases especially
in immunosuppressed patients [28]. HHV-6A dominance
was observed in human immunodeficiency virus infected
individuals, and it may foster the progression of AIDS
[11]. HHV-6A may be an emerging pathogen, and strong
immunosuppression of transplant patients might result in
higher frequency of HHV-6A infection. In our study, the
prevalence of latent HHV-6 infection was not significantly
different between renal transplant patients and healthy
blood donors (13/200 vs. 19/200; p > 0.05). Dominance of
variant B was observed in transplant patients (11/13) and
also in healthy blood donors (18/19 latency). The fre-
quency of variant A was significantly higher in viraemia
then in latency in renal transplant patients (8/9 vs. 2/13;
p = 0.0015). HHV-6 variant A can result from latency, pri-
mary infection or reinfection.
Statistical analysis did not find interaction between
HHV-6 viraemia and clinical symptoms in our study. All
of the patients with HHV-6 viraemia had mild diseases at
the time of sample taking, but most of the patients with-
out HHV-6 infection or with latency also had (9/9 vs.
160/191; p > 0.05). Nevertheless, it was not a follow up
study, and we have no data before and after the observed
HHV-6 viraemia.
HHV-6 and HCMV viraemia was not observed simul-
taneously in renal transplant patients, which does not
exclude the interaction between these viruses.
Conclusions
In this study HHV-6 viraemia was detected early and
late after renal transplantation. In contrast to previous
reports, HHV-6 variant A viraemia was found to be pre-
dominant in these patients. Frequency of variant A was
significantly higher in immunocompromised patients
with active infection then with latency. A follow up
study of renal transplant patients may reveal the clinical
importance of HHV-6A and its potential pathogenetical
role.
Methods
Patients and samples
Two hundred EDTA blood samples from 200 renal
transplant patients (114 men, 86 women, median age
45.5, range 11.2-68.8 years) were taken at different times
after transplantation (median 1271 days, range 3-7115
days). The pre-transplant HHV-6 serostatus of the
patients was not determined. Calcineurin inhibitor, ster-
oid and mycophenolate mofetil was used according to
standard immunosuppressive protocols of patients.
Two hundred EDTA blood samples from 200 healthy
blood donors were also collected (75 men, 125 women,
median age 39, range 10-74 years).
Regional and Institutional Ethics Committee of Uni-
versity of Debrecen approved all of the studies. All
patients gave their written informed consent.
Table 2 Clinical data of 200 renal transplant patients
Number of patients
HHV-6+ HHV-6- HCMV+ HCMV-
Respiratory symptoms 2 78 3 77
Respiratory symptoms with fever 5 53 1 57
Respiratory and gastrointestinal symptoms 1 1 0 2
Gastrointestinal symptoms 1 10 2 9
Gastrointestinal symptoms with fever 0 6 0 6
Fever 0 12 0 12
No clinical symptoms 0 31 1 30
Total 9 191 7 193
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Qualitative and quantitative PCR of HHV-6
Nucleic acid from white blood cells (WBC) (1.5 × 106
cells/blood sample) and 200 μL plasma (centrifuged for
10 min at 180 × g at 4°C) was isolated by High Pure
Viral Nucleic Acid Kit (Roche, Switzerland) according to
the manufacturer’s instructions. Nucleic acid was eluted
in 50 μL and stored at -20°C until usage.
Variant-specific nested PCR amplification of HHV-6
DNA was performed in a final volume of 20 μL contain-
ing 5 μL DNA solutions as described previously [29].
To distinguish between latent and active HHV-6 infec-
tion, reverse transcription PCR (RT-PCR) was used as
described previously [30].
The effectiveness of DNA and RNA isolation were
controlled by use of PCR and RT-PCR amplification of
b-globin DNA and GAPDH mRNA.
Absolute quantification of HHV-6 DNA using real-
time PCR was performed following the method of Bou-
tolleau et al [31]. For calibration curve plasmid DNA
(pGL2-Basic vector, Promega, USA) containing HHV-6
insert was used.
HCMV pp65 antigenaemia
HCMV reactivation was examined by pp65-antigenae-
mia using CINAkit (Argene, France) according to the
manufacturer’s instructions.
Statistical analysis
Chi sqare test and Fisher’s exact test were used to asses
the difference in frequency for categorical variables.
Mann-Whitney U test was applied for continuous vari-
ables. Difference was considered significant if p value
was less then 0.05.
Acknowledgements
This work was supported by grants from the Hungarian Scientific Research
Fund (OTKA 73145).
Author details
1Institute of Medical Microbiology, University of Debrecen, Nagyerdei krt. 98.,
Debrecen, Hungary. 2Institute of Surgery, University of Debrecen, Nagyerdei
krt. 98., Debrecen, Hungary.
Authors’ contributions
ECs contributed to the conception and design of the study and acquisition
of funding, carried out the sample collection, nucleic acid isolation, nested
PCR, RT-PCR, viral load assays and drafted the manuscript. BM contributed to
the sample collection, nucleic acid isolation, nested PCR, RT-PCR. AL
provided the clinical samples and clinical data. TG contributed to positive
controls and plasmid production. JK performed statistical analysis. LG
contributed to the acquisition of funding and revised the manuscript. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 27 May 2011 Accepted: 15 August 2011
Published: 15 August 2011
References
1. Irving WL, Cunningham AL: Serological diagnosis of infection with human
herpesvirus type 6. Br Med J 1990, 300:156-159.
2. Ablashi DV, Balachandran N, Josephs SF, Hung CL, Krueger GR, Kramarsky B,
Salahuddin SZ, Gallo RC: Genomic polymorphism, growth properties, and
immunologic variations in human herpesvirus-6 isolates. Virology 1991,
184:545-552.
3. Dewhurst S, McIntyre K, Schnabel K, Hall CB: Human herpesvirus 6 (HHV-6)
variant B accounts for the majority of symptomatic primary HHV-6
infections in a population of U.S. infants. J Clin Microbiol 1993, 31:416-418.
4. Fischer SA: Emerging viruses in transplantation: there is more to infection
after transplant than CMV and EBV. Transplantation 2008, 86:1327-1339.
5. Singh N, Carrigan DR: Human herpesvirus-6 in transplantation: an
emerging pathogen. Ann Intern Med 1996, 124:1065-1071.
6. Benito N, Ricart MJ, Pumarola T, Marcos MA, Oppenheimer F, Camacho AM:
Infection with human herpesvirus 6 after kidney-pancreas transplant. Am
J Transplant 2004, 4:1197-1199.
7. Herbein G, Strasswimmer J, Altieri M, Woehl-Jaegle ML, Wolf P, Obert G:
Longitudinal study of human herpesvirus 6 infection in organ transplant
recipients. Clin Infect Dis 1996, 22:171-173.
8. Rosenfeld CS, Rybka WB, Weinbaum D, Carrigan DR, Knox KK, Andrews DF,
Shadduck RK: Late graft failure due to dual bone marrow infection with
variants A and B of human herpesvirus-6. Exp Hematol 1995, 23:626-629.
9. Lehto JT, Halme M, Tukiainen P, Harjula A, Sipponen J, Lautenschlager I:
Human herpesvirus-6 and -7 after lung and heart-lung transplantation. J
Heart Lung Transplant 2007, 26:41-47.
10. Humar A: Reactivation of viruses in solid organ transplant patients
receiving cytomegalovirus prophylaxis. Transplantation 2006, 82:S9-S14.
11. Lusso P: HHV-6 and the immune system: mechanisms of
immunomodulation and viral escape. J Clin Virol 2006, 37(Suppl 1):S4-10.
12. DesJardin JA, Gibbons L, Cho E, Supran SE, Falagas ME, Werner BG,
Snydman DR: Human herpesvirus 6 reactivation is associated with
cytomegalovirus infection and syndromes in kidney transplant recipients
at risk for primary cytomegalovirus infection. J Infect Dis 1998,
178:1783-1786.
13. Gentile G: Post-transplant HHV-6 Diseases. Herpes 2000, 7:24-27.
14. Harma M, Hockerstedt K, Lyytikainen O, Lautenschlager I: HHV-6 and HHV-7
antigenemia related to CMV infection after liver transplantation. J Med
Virol 2006, 78:800-805.
15. Ratnamohan VM, Chapman J, Howse H, Bovington K, Robertson P, Byth K,
Allen R, Cunningham AL: Cytomegalovirus and human herpesvirus 6
both cause viral disease after renal transplantation. Transplantation 1998,
66:877-882.
16. Singh N: Human herpesviruses-6, -7 and -8 in organ transplant
recipients. Clin Microbiol Infect 2000, 6:453-459.
17. Ljungman P, Singh N: Human herpesvirus-6 infection in solid organ and
stem cell transplant recipients. J Clin Virol 2006, 37(Suppl 1):S87-91.
18. Campadelli-Fiume G, Mirandola P, Menotti L: Human herpesvirus 6: An
emerging pathogen. Emerg Infect Dis 1999, 5:353-366.
19. Mori T, Tanaka-Taya K, Satoh H, Aisa Y, Yamazaki R, Kato J, Ikeda Y,
Okamoto S: Transmission of chromosomally integrated human
herpesvirsus 6 (HHV-6) variant A from a parent to children leading to
misdiagnosis of active HHV-6 infection. Transpl Infect Dis 2009, 11:503-506.
20. Bakran A, Hart IJ: Human herpesvirus 6 infection after solid organ
transplantation. Transplantation 2009, 88:757-758.
21. Ljungman P: Molecular monitoring of viral infections after hematopoietic
stem cell transplantation. Int J Hematol 2010, 91:596-601.
22. Abdel Massih RC, Razonable RR: Human herpesvirus 6 infections after
liver transplantation. World J Gastroenterol 2009, 15:2561-2569.
23. Hall CB, Caserta MT, Schnabel KC, Shelley LM, Carnahan JA, Marino AS,
Yoo C, Lofthus GK: Transplacental congenital human herpesvirus 6
infection caused by maternal chromosomally integrated virus. J Infect Dis
2010, 201:505-507.
24. Arbuckle JH, Medveczky MM, Luka J, Hadley SH, Luegmayr A, Ablashi D,
Lund TC, Tolar J, De Meirleir K, Montoya JG, et al: The latent human
herpesvirus-6A genome specifically integrates in telomeres of human
chromosomes in vivo and in vitro. Proc Natl Acad Sci USA 2010,
107:5563-5568.
25. Chapenko S, Folkmane I, Ziedina I, Chistyakovs M, Rozentals R, Krumina A,
Murovska M: Association of HHV-6 and HHV-7 reactivation with the
development of chronic allograft nephropathy. J Clin Virol 2009, 46:29-32.
Csoma et al. Virology Journal 2011, 8:403
http://www.virologyj.com/content/8/1/403
Page 4 of 5
26. Loginov R, Karlsson T, Hockerstedt K, Ablashi D, Lautenschlager I:
Quantitative HHV-6B antigenemia test for the monitoring of transplant
patients. Eur J Clin Microbiol Infect Dis 2010.
27. Dockrell DH, Paya CV: Human herpesvirus-6 and -7 in transplantation. Rev
Med Virol 2001, 11:23-36.
28. Bates M, Monze M, Bima H, Kapambwe M, Clark D, Kasolo FC, Gompels UA:
Predominant human herpesvirus 6 variant A infant infections in an HIV-
1 endemic region of Sub-Saharan Africa. J Med Virol 2009, 81:779-789.
29. Yalcin S, Karpuzoglu T, Suleymanlar G, Mutlu G, Mukai T, Yamamoto T,
Isegawa Y, Yamanishi K: Human herpesvirus 6 and human herpesvirus 7
infections in renal transplant recipients and healthy adults in Turkey.
Arch Virol 1994, 136:183-190.
30. Pradeau K, Bordessoule D, Szelag JC, Rolle F, Ferrat P, Le Meur Y, Turlure P,
Denis F, Ranger-Rogez S: A reverse transcription-nested PCR assay for
HHV-6 mRNA early transcript detection after transplantation. J Virol
Methods 2006, 134:41-47.
31. Boutolleau D, Duros C, Bonnafous P, Caiola D, Karras A, Castro ND,
Ouachee M, Narcy P, Gueudin M, Agut H, Gautheret-Dejean A:
Identification of human herpesvirus 6 variants A and B by primer-
specific real-time PCR may help to revisit their respective role in
pathology. J Clin Virol 2006, 35:257-263.
doi:10.1186/1743-422X-8-403
Cite this article as: Csoma et al.: Dominance of variant A in Human
Herpesvirus 6 viraemia after renal transplantation. Virology Journal 2011
8:403.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Csoma et al. Virology Journal 2011, 8:403
http://www.virologyj.com/content/8/1/403
Page 5 of 5
